Cargando…

2523. Outcomes by Resistance Phenotype and Genotype among Baseline Pathogen in Patients with Complicated Urinary Tract Infection (cUTI) in the Phase 3 CERTAIN-1 Study

BACKGROUND: Taniborbactam is an investigational β-lactamase inhibitor that restores cefepime (FEP) activity against FEP-, carbapenem-, and multidrug-resistant Enterobacterales and Pseudomonas aeruginosa producing serine- and metallo-β-lactamases. Cefepime-taniborbactam (FTB) was superior to meropene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moeck, Greg, Gasink, Leanne, Dorr, Mary Beth, Chen, Hongzi, Woosley, Leah, Mendes, Rodrigo E, Wagenlehner, Florian, Henkel, Tim, McGovern, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678329/ http://dx.doi.org/10.1093/ofid/ofad500.2141

Ejemplares similares

2513. CERTAIN-1 Subgroup Analysis: A Phase 3 Study of Cefepime-Taniborbactam Efficacy in the Treatment of Complicated Urinary Tract Infections (cUTI)
por: Dorr, Mary Beth, et al.
Publicado: (2023)

731. CERTAIN-1: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP)
por: McGovern, Paul C, et al.
Publicado: (2022)

1044 Efficacy of Ceftolozane/Tazobactam vs Levofloxacin in the Treatment of Complicated Urinary Tract Infections (cUTI) caused by Levofloxacin-resistant Pathogens: Results from the ASPECT-cUTI Trial
por: Sakoulas, George, et al.
Publicado: (2014)

874 Risk Factors for Complicated Urinary Tract Infection (cUTI) due to Pseudomonas
por: Mcgregor, Jessina C., et al.
Publicado: (2014)

2523 Noninvasive biomarkers for inflammatory bowel disease: Drawbacks and potential
por: Patel, Vihang, et al.
Publicado: (2018)

2523: Mentor training for KL2 Scholars through vertical integration
por: Merrifield, Angela, et al.
Publicado: (2018)

1031 Comparative Epidemiology of Complicated Urinary Tract Infections (cUTI) by Age among US Hospitals
por: Mocarski, Michelle, et al.
Publicado: (2014)

1521. Heterogeneity of Recent Phase 3 cUTI Clinical Trials with New Antibiotics
por: Bass, Almasa, et al.
Publicado: (2018)

1430. Descriptive Epidemiology of Emergency Department Visits with cUTI in the US, 2012-2018
por: Zilberberg, Marya, et al.
Publicado: (2021)

Learning from 2523 trauma deaths in India- opportunities to prevent in-hospital deaths
por: Roy, Nobhojit, et al.
Publicado: (2017)

PB2523: DI-2-ETHYLHEXYL PHTHALATE (DEHP) INHIBITS HEMOGLOBIN S POLYMERIZATION
por: Camacho, Rodrigo Abreu, et al.
Publicado: (2023)

260 Ceftolozane/Tazobactam for the Treatment of cUTI and cIAI Caused by ESBL-producing Enterobacteriaceae
por: Popejoy, Myra, et al.
Publicado: (2014)

1673. Epidemiology of Complicated Urinary Tract Infections (cUTIs) Presenting in Emergency Departments Across the United States (US)
por: Lodise, Thomas, et al.
Publicado: (2020)

Structured patient interview to assess clinical outcomes in complicated urinary tract infections in the APEKS-cUTI study: pilot investigation
por: Portsmouth, Simon, et al.
Publicado: (2021)

1040 Describing Antibiotic Utilization Patterns and Healthcare Costs for Ambulatory and Inpatient/ED Treatment of Complicated Urinary Tract Infection (cUTI)
por: Karve, Sudeep, et al.
Publicado: (2014)

2523. Optimizing Disclosure of HIV Status to a Diverse Population of HIV-Positive Pediatric Patients at an Urban HIV Clinic in the Southeastern United States
por: Dantuluri, Keerti, et al.
Publicado: (2019)

Clinical management of cUTI, cIAI, and HABP/VABP attributable to carbapenem-resistant Gram-negative infections in Spain
por: Ferrer, Ricard, et al.
Publicado: (2021)

1473. Structured Patient Interview in Complicated Urinary Tract Infections to Assess Clinical Outcomes vs. Investigator’s Evaluation in the APEKS-cUTI Study
por: Portsmouth, Simon, et al.
Publicado: (2019)

666. Efficacy and Safety of Cefiderocol According to Renal Impairment in Patients With Complicated Urinary Tract Infection (cUTI) in a Phase 2 Study
por: Portsmouth, Simon, et al.
Publicado: (2019)

Genotypic characteristics of Uropathogenic Escherichia coli isolated from complicated urinary tract infection (cUTI) and asymptomatic bacteriuria—a relational analysis
por: Maniam, Lalitha, et al.
Publicado: (2023)

1670. Clinical Characteristics and Demographics of Patients with Complicated Urinary Tract Infections (cUTI) and Antibiotic Resistance or Treatment Failure: A Retrospective Database Analysis
por: Sulham, Katherine, et al.
Publicado: (2020)

1682. Health Resource Utilization in Patients with Complicated Urinary Tract Infections (cUTI) and Antibiotic Resistance or Treatment Failure: A Retrospective Database Analysis
por: Sulham, Katherine, et al.
Publicado: (2020)

124. Microbiological Outcomes With Plazomicin (PLZ) Versus Meropenem (MEM) in Patients With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis (AP) in the EPIC Study
por: Keepers, Tiffany R, et al.
Publicado: (2018)

Dual inhibition of BRD4 and PI3K-AKT by SF2523 suppresses human renal cell carcinoma cell growth
por: Zhu, Hua, et al.
Publicado: (2017)

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
por: Wagenlehner, Florian M., et al.
Publicado: (2016)

1683. Hospital Admission Patterns in Adult Patients with Complicated Urinary Tract Infections (cUTIs): Identification of Potentially Avoidable Hospital Admissions Across United States (US) Hospitals
por: Lodise, Thomas, et al.
Publicado: (2020)

1578. Treatments for complicated urinary tract infections (cUTI) caused by multidrug resistant (MDR) Gram-negative (GN) pathogens- a systematic review and network meta-analysis (NMA)
por: Reason, Tim, et al.
Publicado: (2020)

An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by Enterobacterales in Critically Ill Adult Patients
por: Gatti, Milo, et al.
Publicado: (2021)

Asymptomatic Bacteriuria in Clinical Urological Practice: Preoperative Control of Bacteriuria and Management of Recurrent UTI
por: Cai, Tommaso, et al.
Publicado: (2016)

UTI myths and misconceptions
Publicado: (2020)

Leukemia Cutis
por: Rao, Angoori G, et al.
Publicado: (2012)

Cutis Marmorata
Publicado: (1910)

Calcinosis Cutis
por: Chopra, R. N., et al.
Publicado: (1935)

Cutis Laxa
Publicado: (1890)

2035. Clinical and Economic Outcomes in Patients with Complicated Urinary Tract Infection (cUTI) and Complicated Intra-Abdominal Infection (cIAI) in Perú: Impact of Gram-Negative Organisms (GNO) Resistant to Antibiotics
por: Hercilla, Luis, et al.
Publicado: (2019)

LB-3. Oral Tebipenem Pivoxil Hydrobromide is Non-inferior to IV Ertapenem in Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) – Results from the Pivotal ADAPT-PO Study
por: Muir, Lori A, et al.
Publicado: (2020)

1433. Impact of 2019 US Food and Drug Administration (FDA) Guidance on Developing Drugs for Urinary Tract Infection (UTI) on the Perceived Efficacy of Antibiotics for the Treatment of Uncomplicated UTI (uUTI)
por: Henriksen, Anne Santerre, et al.
Publicado: (2021)

Frailty associated urinary tract infections (FaUTIs)
por: Kostakopoulos, Nikolaos A., et al.
Publicado: (2021)

637. Treatment Outcomes in Secondary Analysis Populations of Adult Patients the ALLIUM Phase 3 study Comparing Cefepime-Enmetazobactam to Piperacillin-Tazobactam for Complicated Urinary Tract Infections (cUTI) or Acute Pyelonephritis (AP)
por: Kaye, Keith S, et al.
Publicado: (2021)

Biomechanical Properties of the Skin in Cutis Laxa
por: Kozel, Beth A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qkiq34l4jqqdghqs25vkoh4a3r